MANKIND - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 2.5
Show all parameters (20 more)
🏭 Industry
The pharmaceutical sector is known for relatively stable demand but also intense competition and pricing pressures. Companies typically require significant upfront investment in R&D and manufacturing infrastructure, impacting profitability cycles. Maintaining strong brand recognition and efficient distribution networks are crucial for survival and growth within this industry.
✅ Positive
Mankind Pharma demonstrates consistent profitability with a PAT of 558 Cr this quarter, significantly higher than the previous quarter’s 732 Cr. The company maintains a conservative debt-to-equity ratio of 0.34 indicating a strong balance sheet and efficient capital management.
⚠️ Limitation
The high P/E ratio of 41.5 compared to the industry average of 34.6 suggests the stock may be overvalued, particularly given the recent profit decline. Furthermore, the relatively low ROCE and ROE (13.7% and 13.8%) raise questions about the sustainability of returns relative to capital employed, especially considering the industry's typical margins.
🧾 Long-Term Outlook
Based on the current data, a conservative entry zone would be between 2,050 ₹ and 2,150 ₹, targeting a potential margin recovery while acknowledging the valuation premium. Long-term holding guidance hinges on sustained revenue growth exceeding 10% annually and consistent maintenance of the low debt level. The stock warrants continued monitoring regarding competitive pressures within the sector and any shifts in regulatory landscape affecting pharmaceutical pricing – currently, this appears moderately attractive but carries inherent risks due to its elevated valuation and relatively modest returns relative to industry peers.